Morgan Stanley analyst Mark Purcell downgraded Novartis to Underweight from Equal Weight with an unchanged price target of CHF 88. Purcell and the team expect a rotation from safe-haven pharma into growth/cyclical stocks in 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVS:
- Novartis upgraded to Neutral from Underweight at JPMorgan
- Novartis (NYSE:NVS) Could Loose $245M in Litigation Settlement
- Novartis to pay $245M to settle lawsuit on Exforge medicine, Bloomberg reports
- Sandoz Canada supports Ontario policy change on biosimilars
- Novartis call volume above normal and directionally bullish